clarithromycin, rifabutin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mycobacterium Avium Complex Lung Disease
Conditions
Mycobacterium Avium Complex Lung Disease
Trial Timeline
Aug 1, 1995 → May 18, 2017
NCT ID
NCT00598897About clarithromycin, rifabutin
clarithromycin, rifabutin is a approved stage product being developed by Pfizer for Mycobacterium Avium Complex Lung Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00598897. Target conditions include Mycobacterium Avium Complex Lung Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00598897 | Approved | Completed |
Competing Products
20 competing products in Mycobacterium Avium Complex Lung Disease